- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04603508
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
August 3, 2022 updated by: EMS
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
240
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
- Participants of both sexes, with age greater than or equal to 18 years and less than or equal to 85 years;
- Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and previous therapies at a stable dose in the last 3 months;
- HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose > 100 mg/dL at the screening visit;
- Participants with low or intermediary cardiovascular risk according to the Brazilian guideline on the prevention of cardiovascular diseases in patients with diabetes (2017), which have not reached the goal of LDL-c ≤ 100 mg/dL with lifestyle changes, who are or aren't using low-potency statins;
- BMI (body mass index) > 19 Kg/m2 and ≤ 45 Kg/m2.
Exclusion Criteria:
- Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
- History of alcohol abuse or illicit drug use;
- Participation in a clinical trial in the year prior to this study;
- Pregnancy or risk of pregnancy and lactating patients;
- Known hypersensitivity to the formula components used during the clinical trial;
- Type 1 diabetes mellitus;
- Fasting blood glucose > 300 mg/dL;
- Risk factors for volume depletion;
- Participants with total cholesterol > 500 mg/dL or triglycerides > 500 mg/dL;
- Impaired renal function and end-stage renal disease;
- Participants with known heart failure, class III to IV (New York Heart Association);
- Impaired hepatic function;
- Medical history of pancreatic diseases that may suggest insulin deficiency;
- Bariatric surgery in the last two years and/ or other gastrointestinal surgeries that can cause chronic malabsorption syndrome;
- Condition that, in the investigator's judgment, may favor clinically significant changes in CPK levels;
- Current medical history of cancer and/ or cancer treatment in the last 5 years;
- Participants with known uncontrolled hypothyroidism or TSH levels > 5 mIU/L;
- History of known muscle disease or prior statin intolerance;
- Participants using SGLT2 inhibitors, sulfonylureas and/or insulin therapy or PCSK9 inhibitors;
- Participants who used other medications with prominent action in the control of serum triglyceride and cholesterol levels in the last 4 weeks or who are using low-intensity statins that cannot be replaced by rosuvastatin 10 mg;
- Participants using medications that may interfere with triglyceride and cholesterol metabolism started less than 4 weeks ago or with dose adjustment in the last 4 weeks prior to the screening visit;
- Treatment with anti-obesity drugs for less than 2 months or with dose change in the last 2 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Berlim 25/10
The study is triple-dummy. The patient must take 3 tablets once a day, as follows: 1 tablet Berlim 25/10 association, oral; 1 tablet empagliflozin placebo, oral; 1 tablet rosuvastatin calcium placebo, oral. |
Berlim 25/10 association coated tablet.
Empagliflozin placebo coated tablet.
Rosuvastatin placebo coated tablet.
|
Active Comparator: Empagliflozin + rosuvastatin calcium
The patient must take 3 tablets once a day, as follows: 1 tablet Berlim 25/10 association placebo, oral; 1 tablet empagliflozin , oral; 1 tablet rosuvastatin calcium, oral. |
Empagliflozin 25 mg coated tablet.
Rosuvastatin 10 mg coated tablet.
Berlim 25/10 association placebo coated tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in glycated hemoglobin (HbA1c) levels.
Time Frame: 120 days
|
120 days
|
Percent change from baseline of LDL-c levels.
Time Frame: 120 days
|
120 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events recorded during the study.
Time Frame: 150 days
|
150 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2023
Primary Completion (Anticipated)
April 1, 2025
Study Completion (Anticipated)
August 1, 2025
Study Registration Dates
First Submitted
October 21, 2020
First Submitted That Met QC Criteria
October 21, 2020
First Posted (Actual)
October 26, 2020
Study Record Updates
Last Update Posted (Actual)
August 5, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Lipid Metabolism Disorders
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dyslipidemias
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Rosuvastatin Calcium
- Calcium
- Empagliflozin
- Calcium, Dietary
Other Study ID Numbers
- EMS0919 - Berlim 25/10
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on BERLIM 25/10 association
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil
-
Idorsia Pharmaceuticals Ltd.Completed
-
Cymra Life SciencesCompletedPain | Back Pain | Chronic Pain | Neck Pain | Pain, Chronic | CBD | Pain, Back | Pain, Neck | THCAustralia
-
Insmed IncorporatedCompletedNon-Cystic Fibrosis BronchiectasisUnited States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
-
Insmed IncorporatedActive, not recruitingNon-Cystic Fibrosis BronchiectasisNew Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
-
Kuopio University HospitalCompleted
-
Idorsia Pharmaceuticals Ltd.CompletedHepatic ImpairmentSwitzerland
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompletedDiabetes Mellitus, Type 2China
-
EMSRecruitingDyslipidemia | HypertriglyceridemiaBrazil
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon